BGT226

• Description :

  BGT226 (NVP-BGT226) is a PI3K (with IC50s of 4 nM, 63 nM and 38 nM for PI3Kα, PI3Kβ and PI3Kγ) /mTOR dual inhibitor which displays potent growth-inhibitory activity against human head and neck cancer cells[1][2].

• Product Name Alternative :

  NVP-BGT226

• UNSPSC :

  12352005

• Target :

  Autophagy; mTOR; PI3K

• Type :

  Reference compound

• Related Pathways :

  Autophagy; PI3K/Akt/mTOR

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/BGT226.html

• Purity :

  99.85

• Solubility :

  DMSO : 10 mg/mL (ultrasonic; warming; heat to 60°C)

• Smiles :

  O=C(N1C2=CC=C(N3CCNCC3)C(C(F)(F)F)=C2)N(C)C4=C1C5=CC(C6=CC=C(OC)N=C6)=CC=C5N=C4

• Molecular Formula :

  C28H25F3N6O2

• Molecular Weight :

  534.53

• References & Citations :

  [1]Markman B, et al. Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors. Ann Oncol. 2012 Sep;23 (9) :2399-408.|[2]Chang KY, et al. Novel phosphoinositide 3-kinase/mTOR dual inhibitor, NVP-BGT226, displays potent growth-inhibitory activity against human head and neck cancer cells in vitro and in vivo. Clin Cancer Res. 2011 Nov 15;17 (22) :7116-26.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 2

• Isoform :

  MTOR; PI3Kα; PI3Kβ; PI3Kγ

• Citation 01 :

  Molecules. 2020 Apr 23;25 (8) :1980.|Arch Pharm (Weinheim) . 2024 Sep;357 (9) :e2400066.|Front Pharmacol. 2020 Nov 11;11:580407.|Harvard Medical School LINCS LIBRARY|Research Square Print. 2023 Mar 9.|Sci Transl Med. 2018 Jul 18;10 (450) :eaaq1093.

• CAS Number :

  [915020-55-2]